Subscribe To
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Genenta to present at upcoming scientific and investor conferences
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developin...
September 6, 2023, 7:00 am
Allovir: several late-stage programs make this worth a look
Positive final results from the phase 2 study, using posoleucel for BK Virus, were presented at the American Transplant Congress 2023. Discussions wit...
July 1, 2023, 3:48 am
Nextcure presents non-clinical data defining the mechanism of nc525 at the 2023 federation of clinical immunology societies (focis) annual meeting
BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering...
June 21, 2023, 8:05 pm
Helocyte announces $3.22 million grant from the national cancer institute for triplex phase 2 clinical trial program
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-spec...
June 15, 2023, 12:00 pm
Why is avrobio (avro) stock up 83% today?
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has...
May 22, 2023, 11:43 am
Tscan therapeutics presents preliminary phase 1 clinical results on tsc-100 and tsc-101 at the american society of gene & cell therapy 26th annual meeting
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell...
May 17, 2023, 7:00 am
Theriva biologics reports first quarter 2023 operational highlights and financial results
– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancr...
May 11, 2023, 12:00 pm
Omeros: worst has been priced in, we like its igan pipeline, initiating with a buy
Omeros corporation's hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) ...
February 4, 2023, 8:33 am
In8bio to present positive early data from ongoing phase 1 study of inb-100 at the 64th american society of hematology annual meeting
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovat...
November 3, 2022, 9:10 am
Vor bio to present at keystone symposia precision genome engineering meeting
Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hemat...
April 25, 2022, 8:00 am
Jasper therapeutics to present updated data on jsp191 conditioning in scid patients at the 2022 clinical immunology society annual meeting
REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on ...
March 31, 2022, 8:00 am
Fda holds mustang bio's gene therapy ind for compromised immune system disorder
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru...
January 25, 2022, 7:10 am
Fda holds mustang bio's gene therapy ind for compromised immune system disorder
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru...
January 25, 2022, 7:10 am
Fda holds mustang bio's gene therapy ind for compromised immune system disorder
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru...
January 25, 2022, 7:10 am
Fda gives nod to tscan therapeutics' early-stage trial of tsc-100 in hematologic malignancies
The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies p...
January 24, 2022, 12:30 pm
Fda gives nod to tscan therapeutics' early-stage trial of tsc-100 in hematologic malignancies
The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies p...
January 24, 2022, 12:30 pm